Edition:
United States

People: Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.15USD
11:02am EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.15
Open
$2.17
Day's High
$2.19
Day's Low
$2.14
Volume
17,142
Avg. Vol
43,819
52-wk High
$4.04
52-wk Low
$1.72

Hulme, Allison 

Dr. Allison J. Hulme, Ph.D., serves as Chief Operating Officer, Head - Research & Development, Director of Sophiris Bio Inc. From January 2005 to October 2009, Dr. Hulme served as Executive Vice President of Autoimmune, Tysabri, Global Development and Head of Autoimmune and Tysabri Franchise at Elan Corporation, plc (also known as Elan Pharmaceuticals), a neuroscience-focused biotechnology company. From October 1995 to January 2005, she served in various roles of increasing responsibility, including, Global Project Leader for Tysabri, Head of Tysabri Business Enterprise and Senior Vice President of Global Development at Elan Pharmaceuticals. Previously, Dr. Hulme held several positions in clinical research at Glaxo Wellcome Pharmaceuticals in the United Kingdom and served as lecturer at Luton University.

Basic Compensation

Total Annual Compensation, USD 350,100
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 254,435
Fiscal Year Total, USD 604,535

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --